Cerenome (PSTV) Asset Writedowns and Impairment (2010 - 2015)
Plus Therapeutics (PSTV) posted quarterly Asset Writedowns and Impairment of -$105000.0 for Q4 2015, down 150.0% year-over-year from $210000.0 in Q4 2014, and down 150.0% quarter-over-quarter from -$42000.0 in Q4 2014.
Cerenome (PSTV) Asset Writedowns and Impairment (2010 - 2015) Analysis & Trends
Plus Therapeutics (PSTV) has reported Asset Writedowns and Impairment for 6 consecutive years, with -$105000.0 the latest figure, recorded in Q4 2015.
- In Q4 2015, Asset Writedowns and Impairment fell 150.0% year-over-year to -$105000.0; the TTM figure through Dec 2015 stood at -$105000.0 (down 109.69% YoY), while the FY2020 annual figure was $107000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment retreated to -$105000.0 in Q4 2015 per PSTV's latest filing, from -$42000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $750000.0 in Q3 2013 and bottomed at -$105000.0 in Q4 2015.
- Historically, Asset Writedowns and Impairment has averaged $161588.2 across 5 years, with a median of $87000.0 in 2013.
- Annual changes were most pronounced in 2012 — Asset Writedowns and Impairment slumped 214.29% — and 2013, when it surged 837.5%.
- Plus Therapeutics' Asset Writedowns and Impairment stood at $209000.0 in 2011, then sank by 78.47% to $45000.0 in 2012, then jumped by 351.11% to $203000.0 in 2013, then tumbled by 120.69% to -$42000.0 in 2014, then slumped by 150.0% to -$105000.0 in 2015.
- Business Quant data shows PSTV's Asset Writedowns and Impairment at -$105000.0 in Q4 2015, -$42000.0 in Q4 2014, and $290000.0 in Q3 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | -105,000.00 |
| Dec 31, 2015 | -105,000.00 |
| Dec 31, 2014 | -42,000.00 |
| Dec 31, 2014 | -42,000.00 |
| Sep 30, 2014 | 290,000.00 |
| Sep 30, 2014 | 290,000.00 |
| Jun 30, 2014 | 371,000.00 |
| Jun 30, 2014 | 371,000.00 |
| Mar 31, 2014 | 465,000.00 |
| Mar 31, 2014 | 465,000.00 |
| Dec 31, 2013 | 203,000.00 |
| Dec 31, 2013 | 203,000.00 |
| Sep 30, 2013 | 750,000.00 |
| Sep 30, 2013 | 750,000.00 |
| Jun 30, 2013 | 101,000.00 |
| Jun 30, 2013 | 101,000.00 |
| Mar 31, 2013 | 87,000.00 |
| Mar 31, 2013 | 87,000.00 |
| Dec 31, 2012 | 45,000.00 |
| Dec 31, 2012 | 45,000.00 |